

Letter to the Editor

6 Dissecting Cellulitis Associated With Hormone
7 Therapy in a Transgender Man

9 To the Editor,

Q2 Dissecting cellulitis (DC) is a chronic, neutrophilic scarring alopecia that mainly affects the vertex and occipital areas of the scalp.¹ Its hallmark clinical features include papules, pustules, nodules, and abscesses. This condition predominantly afflicts young black men of African descent, with rare occurrences in women and children, as evidenced by limited reports.^{2,3} While the precise causes remain elusive, genetic, and environmental factors, local trauma, imbalance of the scalp microbiota, and androgens seem to play a role.^{2,4}

This is the case of a 55-year-old Fitzpatrick phototype IV transgender male on androgen hormone therapy. The patient had been on intra-muscular testosterone for over a decade and presented with a several-month history of scalp nodules, abscesses, pruritus, and alopecia on the vertex and mid-scalp (Fig. 1A). Trichoscopy examination was noticeable for broken hairs, pustules, 3D yellow dots, scaling, erythema, polytrichia, and areas with absent follicular openings (Fig. 1B, C).

The word "transgender" is a generic term to describe persons whose gender identity or expression differs from the biological sex assigned at birth (between 0.1% and 2% of the population).¹ These individuals may choose to undergo gender-affirming hormone therapy to align

their physical characteristics with their affirmed gender,⁶ which in our patient consisted of testosterone therapy.⁴ The biological plausibility between gender/sexual hormones and the disease has been proposed due to the remarkable male predominance of this condition.^{2,3,5} DC is part of the "follicular occlusion tetrad" wherein the obstruction of the follicular infundibulum is considered the initial event.^{1,3,5}

Testosterone affects the sebaceous gland primarily through local conversion to dihydrotestosterone (DHT) via 5-alpha reductase Type 1.⁶ Among all androgens, DHT binds cytoplasmic androgen receptors with the highest affinity. These receptors are expressed most abundantly in sebocytes, eccrine sweat epithelium, and dermal papilla cells and trigger a chain of metabolic events, which lead to excessive production of keratinocytes and sebum.⁶

The proliferating ductal lining cells, unable to escape the infundibulum of the pilosebaceous units, form a plug.⁶⁻⁸ Follicular dilation followed by rupture, keratin debris, and the presence of bacteria stimulates inflammation, abscess formation, and sinus tracts, eventually causing alopecia.^{1,5} The role of androgenic anabolic steroids on DC is further supported by Motosko et al. who described 1 case of abrupt onset of the disease in a male who used androgenic anabolic steroids for recreation for performance enhancement.⁹ Similarly, in our patient, the prolonged use of testosterone for gender-affirming purposes seemed to be the key factor inducing the disease in an otherwise unusual candidate.

DC is a rare condition that affects almost exclusively men with remarkable psychosocial impact. Its presence in a transgender man on androgenic therapy seems to be yet another piece of evidence of its




Fig. 1. (a) Clinical image of a 55-year-old transgender man on androgen hormone therapy showing nodules, pustules and alopecia on the vertex and mid-scalp. (b) Trichoscopic image demonstrating a three-dimensional yellow dot (yellow arrow), polytrichia (green arrow), a large brown dot (orange arrow), diffuse erythema (white arrow), cutaneous clefts with emerging hairs (pink arrow), peri- and interfollicular scale (purple arrow), and broken hairs (red arrow). (c) Trichoscopy image showing a three-dimensional yellow dot (yellow arrow), polytrichia (green arrow), structureless area (blue arrow), short regrowing hair (orange arrow), diffuse erythema (white arrow), peri and interfollicular scales (purple arrow), black dots (black arrow), and broken hair (red arrow).

54 pathogenic puzzle. Trichoscopy is useful in detecting the evolutionary
 55 stages of DC, early diagnosis, and monitoring the patient during treat-
 56 ment.¹⁰

57 In conclusion, DC is a stigmatizing disease with a prominent impact
 58 on quality of life. With the modern use of androgen therapy for gen-
 59 der reassignment, physicians should be aware of the possibility of this
 60 condition in transgender males on hormone treatment to tackle its signs
 61 before irreversible damage occurs.

62 Statement

63 The patient in this manuscript has given written informed consent
 64 to publication of the case details.

65 Funding source

66 None.

67 Conflict of interest

68 The authors declare no conflict of interests regarding this paper.

69 Data availability statement

70 All data generated or analyzed during this study are included in this
 71 article. Further enquiries can be directed to the corresponding author.

72 References

73 1. Nussbaum D, Desai S, Nelson K, Saardi K, Friedman A. An up-to-date approach to
 74 the management of dissecting cellulitis. *J Drugs Dermatol*. 2022;21:800–802.

2. Melo DF, Ramos PM, Machado CJ, et al. Dissecting cellulitis in women: a retrospec-
 75 tive multicenter study with 17 patients. *Int J Dermatol*. 2022;61:e427–e430.
 76 3. Lee CN, Chen W, Hsu CK, Weng TT, Lee JY, Yang CC. Dissecting folliculitis (dissecting
 77 cellulitis) of the scalp: a 66-patient case series and proposal of classification. *J Dtsch
 78 Dermatol Ges*. 2018;16:1219–1226.
 79 4. Gao JL, Sanz J, Tan N, King DS, Modest AM, Dommasch ED. Androgenetic alopecia
 80 incidence in transgender and gender diverse populations: a retrospective compara-
 81 tive cohort study. *J Am Acad Dermatol*. 2023;89:504–510.
 82 5. Sung KY, Lee S, Jeong Y, Lee SY. Dissecting cellulitis of the scalp: a diagnostic
 83 challenge. *Arch Plast Surg*. 2020;47:631–632.
 84 6. Motosko CC, Zakhem GA, Pomeranz MK, Hazen A. Acne: a side-effect of masculin-
 85 izing hormonal therapy in transgender patients. *Br J Dermatol*. 2019;180:26–30.
 86 7. Hazarika N. Acne vulgaris: new evidence in pathogenesis and future modalities of
 87 treatment. *J Dermatolog Treat*. 2021;32:277–285.
 88 8. Hermosura Almazan T, Kabigting FD. Dermatologic care of the transgender patient.
 89 *Dermatol Online J*. 2016;22:13030.
 90 9. Kurtzman DJB, Alexander CE. Image gallery: dissecting cellulitis of the scalp follow-
 91 ing anabolic steroid use. *Br J Dermatol*. 2017;177:e160.
 92 10. Melo DF, Lemes LR, Pirmez R, Duque-Estrada B. Trichoscopic stages of dissecting
 93 cellulitis: a potential complementary tool to clinical assessment. *An Bras Dermatol*.
 94 2020;95:514–517.
 95

J.L. Rodrigues Machado ^a, M. Domingos Almeida ^{ID b,*},
 R.F. Cortez de Almeida ^b, D. Fernandes Melo ^b

Q1 96

97

^a Department of Dermatology, Faculdade IPEMED de Ciências Médicas
 (AFYA), Rio de Janeiro, Brazil

98

99

^b Department of Dermatology, Rio de Janeiro State University (UERJ), Rio
 de Janeiro, Brazil

100

101

* Corresponding author.

102

E-mail address: maitealmeida2022@gmail.com
 (M. Domingos Almeida).

103

104